Key Slides on ART Selection Considerations for an Older Woman With Fatty Liver Disease and Newly Diagnosed HIV

Review this patient case and the relevant data and guideline recommendations that inform optimal ART selection for patients with HIV and fatty liver disease
Paul E. Sax, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 219 KB
Released: August 12, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Concise Clinical Care Options (CCO) presentation by Darrell H. S. Tan, MD, FRCPC, PhD, on approved and guideline-recommended oral HIV PrEP regimens

person default Darrell H. S. Tan, MD, FRCPC, PhD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: July 29, 2021 Expired: July 28, 2022

ZeNix: bedaquiline, pretomanid, plus varying doses and durations of linezolid in patients with highly resistant TB, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 26, 2021

Interim results from the Phase II CALIBRATE study of lenacapavir in treatment-naive PLWH, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 24, 2021

REACH study: adherence to dapivirine vaginal ring and oral PrEP among African females 16-21 years, in Clinical Care Options (CCO) report from IAS 2021

Released: July 24, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue